23 research outputs found
Investigation of a Microcystis aeruginosa cyanobacterial freshwater harmful algal bloom associated with acute microcystin toxicosis in a dog
No full textMicrocystin poisoning was diagnosed in a dog exposed to a Microcystis aeruginosa
dominated freshwater harmful algal bloom at Milford Lake, Kansas, which occurred during the summer of 2011. Lake water microcystin concentrations were determined at intervals during the summer, using competitive enzyme-linked immunosorbent assays, and indicated extremely high, localized microcystin concentrations of up to 126,000 ng/ml. Multiple extraction and analysis techniques were utilized in the determination of free and total microcystins in vomitus and liver samples from the poisoned dog. Vomitus and liver contained microcystins, as determined by enzyme-linked immunosorbent assays, and the presence of microcystin LR was confirmed in vomitus and liver samples using liquid chromatography coupled with tandem mass spectrometry. Major toxic effects in a dog presented for treatment on the day following exposure included fulminant liver failure and coagulopathy. The patient deteriorated rapidly in spite of aggressive treatment, and was euthanized. Postmortem lesions included diffuse, acute, massive hepatic necrosis and hemorrhage, and acute necrosis of the renal tubular epithelium. A diagnosis of microcystin poisoning was based on the demonstration of M. aeruginosa and microcystin-LR in the lake water, as well as in vomitus produced early in the course of the poisoning, the presence of microcystin-LR in liver tissue, and on a typical clinical course
Symblepharon in kittens: a retrospective study of 40 kittens and 54 eyes (2002–2022)
No full textObjectives:
The aim of this study was to retrospectively evaluate the signalment, treatment, surgical technique and outcomes for feline symblepharon.
Methods:
A retrospective medical record review and standardized grading of clinical descriptions and photographs was undertaken.
Results:
Forty kittens (54 eyes) aged 3–46 weeks had symblepharon of five types in various combinations: eyelid deformation (24 kittens; 32 eyes); ankyloblepharon (four kittens; four eyes); conjunctiva-to-conjunctiva (11 kittens; 12 eyes); third eyelid-to-conjunctiva (24 kittens; 29 eyes); and corneoconjunctival adhesions (14 kittens; 16 eyes). At initial presentation, 23 (43%) eyes were affected by one type of symblepharon, 25 (46%) eyes by two types and six (11%) eyes by three types; 11 (20%) corneas were ulcerated. Twenty-four (44%) eyes of 18 (45%) kittens were managed medically. Surgery was performed under general anesthesia/sedation (30 occasions) or topical anesthesia (21 occasions) on 30 (56%) eyes of 22 kittens; 12 eyes (40%) underwent multiple surgeries. Four techniques were commonly employed: separation of conjunctival-to-conjunctival adhesions ± eyelid margins (14 eyes); resection of third eyelid adhesions ± temporary tacking of the third eyelid (modified Arlt’s pterygium technique; 18 eyes); en bloc resection of the third eyelid (two eyes); and separation of corneoconjunctival adhesions (14 eyes). Median duration of follow-up was 55 days (range 1–1051). Median symblepharon grade in kittens treated surgically improved for all types except corneoconjunctival symblepharon. Median symblepharon grade in kittens receiving medical management remained the same or improved. Corneoconjunctival symblepharon opacity decreased for eyes treated surgically but increased for eyes treated medically. Three eyes were enucleated due to complications of corneoconjunctival symblepharon. At final presentation, symblepharon persisted in 46 (85%) eyes; however, menace response was evident in 13/16 eyes and dazzle reflex in 23/23 eyes.
Conclusions and relevance:
Symblepharon is a heterogeneous group of conditions with diverse anatomic involvement, clinical appearance and impact, optimal treatment and prognosis for vision.This article is published as Shiraishi, Hikaru, Karen M. Vernau, Soohyun Kim, Kathryn L. Good, Steven R. Hollingsworth, Lionel Sebbag, Elizabeth Montgomery et al. "Symblepharon in kittens: a retrospective study of 40 kittens and 54 eyes (2002–2022)." Journal of Feline Medicine and Surgery 25, no. 2 (2023).
DOI: 10.1177/1098612X221150160.
Copyright 2023 The Author(s).
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
Posted with permission
Premio Fondazione Cominelli per il gioiello contemporaneo: Cominelli Foundation for Contemporary Jewellery 2012
No full textThird Edition
Award Cominelli Foundation for Contemporary JewelleryThe selected artists :ADAM GRINOVICH, ALEXANDER BLANK, ANA ALBUQUERQUE, BERNHARD STIMPFL-ABELE JI CHANG CHAI,CHIARA SCARPITTI, DANIA CHELMINSKY, DIANA DUDEK, EMMANUEL LACOSTE, FARRAH AL DUJAILI, FLAVIA FENAROLI, GABI VEIT, HEIDEMARIE HERB, JASMIN MATZAKOW, JUDY MC CAIG, JIE SUN, JO POND, KATHARINA MOCH, LAURA BRADSHAW- HEAP, LYDIA HIRTE, LISA BJIORKE, GIGI MARIANI, MAJA HOUTMAN, MARIA EUGENIA LOPEZ, MARIANNE SCHLIWINSKI, MARI ISHIKAWA, MARTA HRYC, MAURIZIO STAGNI, MICHELLE SEBBAG, MOHSEN AMINI, PETER HOOGEBOOM, RIA LINS, RITSUKO OGURA, SANNA SVEDESTEDT, SEUL-GI KWON, SILKE TREKEL, STEPHEN BOTTOMLEY, SUNGHO CHO, SUSAN CROSS, TERESA DANTAS , VIKTORIA MUNZKER, YOUNGHEE HONG.Stephen Bottomley: 2 pieces of jewellery selected for this award:Blue striped patch, Brooch 2011. Oxidised silver, enamel, gold and stainless steelBlue Patch, Broock 2011. Oxidised silver, enamel, gold and stainless steelSusan Cross: 2x pieces of jewellery selected for this award:Two Hoops, Neckpiece 2009. oxidised silver & 18ct goldLooping the Loop, Brooch 2008. oxidised silver & 18ct goldSelection: Ms. Maria Cristina Bergesio author of important publications on contemporary jewellery selected 40 participants from an open international application process.The Jury:
Michele Cassarino, chairman of the Cominelli Foundation Daniel Kruger, goldsmith, teacher sculpture/jewelry Art School in Halle Maria Cristina Bergesio, historian of jewellery and contemporary jewellery Mirella Cisotto Nalon, head of cultural activity, the Council of Padua Rita Marcangelo, gallery owner, administrator of the Cominelli Foundation’s Permanent Collection Massimo Tedeschi, editor-in-chief Corriere della Sera, Brescia supplement Ludwig Reinhold, director of Art Aurea magazineThe exhibition will be held in the splendid 17th century building, overlooking the Salò Gulf, headquarters of the Cominelli Foundation. The prizes will be awarded at the opening on Saturday 1st September 2012.This year for the project Training Courses in Contemporary Jewellery there will be an exhibition dedicated to jewellery training in the Edinburgh Art College. The head of department, Stephen Bottomley, will present a selection of jewellery made by the students and a report on the training courses in this field<br/
Multicenter prospective randomized study comparing the technique of using a bovine pericardium biological prosthesis reinforcement in parietal herniorrhaphy (Tutomesh TUTOGEN) with simple parietal herniorrhaphy, in a potentially contaminated setting
No full textThe use of parietal synthetic prosthetic reinforcement material in potentially contaminated settings is not recommended, as there is a risk that the prosthesis may become infected. Thus, simple parietal herniorrhaphy, is the conventional treatment, even though there is a significant risk that the hernia may recur. Using new biomaterials of animal origin presently appears to offer a new therapeutic solution, but their effectiveness has yet to be demonstrated. The purpose of this multicenter prospective randomized single-blind study was to compare the surgical treatment of inguinal hernia or abdominal incisional hernia by simple parietal herniorrhaphy without prosthetic reinforcement (Group A), with Tutomesh TUTOGEN biological prosthesis reinforcement parietal herniorrhaphy (Group B), in a potentially contaminated setting. We examined early postoperative complications in the first month after the operation, performed an assessment after one year of survival without recurrence and analyzed the quality of life and pain of the patients (using SF-12 health status questionnaire and Visual Analog Pain Scale) at 1, 6, and 12 months, together with an economic impact study. Hundred and thirty four patients were enrolled between January 2009 and October 2010 in 20 French hospitals. The groups were comparable with respect to their enrollment characteristics, their history, types of operative indications and procedures carried out. At one month post-op, the rate of infectious complications (n(A)?=?11(18.33%) vs. n(B)?=?12(19.05%), p?=?0.919) was not significantly different between the two groups. The assessment after one year of survival without recurrence revealed that survival was significantly greater in Group B (Group A recurrence: 10, Group B: 3; p?=?0.0475). No difference in the patients' quality of life was demonstrated at 1, 6, or 12 months. However, at the 1 month follow-up, the "perceived health" rating seemed better in the group with Tutomesh (p?=?0.022). No significant difference between the two parietal repair groups was observed during the follow-ups with respect to the criterion of pain (using a visual analog scale). There was a significant difference between the two parietal repair groups with regard to the number of days spent in intensive care unit, in favor of the Tutomesh technique (p?=?0.010). The use of a Tutomesh bioprosthesis for hernia repair or postincisional hernia in a potentially contaminated workplace reduces the risk of short-term recurrence without increasing overall comorbidity
Cascade counselling and testing. Recommendations of the European Society of Human Genetics.
No full textCascade testing (CT) is an effective instrument for identifying an index patient's relatives at high risk of a heritable condition enabling informed decision-making on preventive interventions and reproductive choice. However, CT remains underutilised and faces barriers. Discussions are ongoing on how to optimise informing family members and testing uptake in a responsible manner. The European Society of Human Genetics (ESHG) contributes to this debate and provides recommendations based on an ethical analysis of when CT is justified, or may be less compelling, considering proportionality and the judicious use of finite resources. ESHG underscores the strong consensus regarding the 'moral architecture' of CT in cases of a high risk of serious, avoidable harm. In such cases, a more active approach towards CT is suggested, including a more directive approach in counselling, more active support for the proband, direct contacting, and balancing confidentiality when this is necessary to avoid a high risk of serious harm, taking account of national regulations and jurisdictions. In contrast, more caution is advised in more complex cases where the balance of benefits and harms of CT is less clear, such as when penetrance is low, and actionability or medical treatment is limited. This more cautious approach does not call for directivity, direct contact or the relaxing of medical confidentiality. The focus, then, shifts to cascade counselling, rather than cascade testing. In some cases, CT may not be proportional or appropriate given the balance between benefits and harms, also in view of available resources. [Abstract copyright: © 2025. The Author(s).
Recommended from our members
Author Correction: Identification of genes required for eye development by high-throughput screening of mouse knockouts
No full textIn the original published version of the article, Valerie Vancollie was mistakenly omitted from the list of members of the International Mouse Phenotyping Consortium. In addition, recognition of funding from Wellcome Trust grant WT098051 was mistakenly omitted from the Acknowledgements.The errors have been corrected in both the PDF and HTML versions of the paper
Erratum: Author Correction: Identification of genes required for eye development by high-throughput screening of mouse knockouts.
No full textAuthor Correction: Identification of genes required for eye development by high-throughput screening of mouse knockouts (Communications Biology, (2018), 1, 1, (236), 10.1038/s42003-018-0226-0).
No full textThis is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. In the original published version of the article, Valerie Vancollie was mistakenly omitted from the list of members of the International Mouse Phenotyping Consortium. In addition, recognition of funding from Wellcome Trust grant WT098051 was mistakenly omitted from the Acknowledgements.The errors have been corrected in both the PDF and HTML versions of the paper
Position statement and guidelines about Endoscopic Sleeve Gastroplasty (ESG) also known as “Endo-sleeve”
No full textInternational audienceIS ESG EFFECTIVE IN THE TREATMENT OF OBESITY AND ASSOCIATEDCOMORBIDITIES?: Endoscopic Sleeve Gastroplasty (ESG) is more effective than lifestyle modifications alone for weight loss and improving obesity-related comorbidities. While it has less effect on weight loss compared to Laparoscopic Sleeve Gastrectomy (LSG) in the short to medium term, it offers similar comorbidities resolution to LSG. IS ESG A SAFE PROCEDURE, AND WHAT ARE ITS RISKS?: The safety profile of ESG is consistently supported in the literature. Surgical complications after ESG, ranging from 1.5 to 2.3%, such as bleeding, perforation, fistula, or upper bowel obstruction, are rare and typically managed endoscopically. The incidence of new-onset gastro-esophageal reflux disease (GERD) is deemed negligible and occurs less frequently after ESG compared to SG. WHAT ARE THE INDICATIONS AND MANAGEMENT METHODS?: Multidisciplinary care for patients undergoing ESG should be provided in an accredited center authorized to perform bariatric and metabolic surgery, with validation through a multidisciplinary consultation meeting (RCP). Perioperative management should be personalized and ideally modeled after the protocols already in place for bariatric and metabolic surgery to ensure satisfactory and lasting weight and metabolic outcomes. Adherence to follow-up visits is a significant predictor of successful weight loss outcomes after ESG. Additionally, all endoscopic surgical procedures should be documented in a registry affiliated with a recognized scientific society, as is standard for other bariatric surgical procedures. WHICH HEALTHCARE PROFESSIONALS CAN PERFORM ESG?: ESG must be performed by a practitioner trained in endoscopy and obesity management, capable of ensuring thorough preoperative care and comprehensive postoperative follow-up, supported by an experienced multidisciplinary team. In France, Notice No. 2021.0040/AC/SEAP of June 10, 2021, issued by the Haute Autorité de santé (HAS) college, specifies that "the technology of ESG via the trans-oral approach, involving wide plication of the greater gastric curvature […] with an endoscopic suture placement device, enables a gastroenterologist or a visceral and digestive surgeon to perform gastric plication through digestive endoscopy by placing sutures in the stomach". Ideally, this should take place in an accredited center authorized to perform bariatric and metabolic surgery, such as those approved by the Agence régionale de santé (ARS), in accordance with Article R6123-212 of December 2022 of the French Public Health Code. WHAT ARE THE RECOMMENDATIONS AND VIEWS OF OTHER INTERNATIONAL SCIENTIFICSOCIETIES?: ESG is an integral part of the therapeutic arsenal available to bariatric and metabolic surgeons, offering an effective and valuable treatment option for obesity in specific patient populations. The International Federation for the Surgery of Obesity (IFSO) Bariatric Endoscopy Committee, following a comprehensive systematic review and meta-analysis, endorsed ESG as an effective and valuable treatment for obesity. ESG is particularly beneficial for patients with class I and II obesity, as well as for those with class III obesity who are not suitable candidates for metabolic bariatric surgery. Additionally, it can be proposed as an addition to lifestyle interventions in adolescent patients with class II obesity. The SOFFCOMM endorses endoscopic sleeve gastroplasty (ESG) as an effective and valuable treatment for obesity and highlights the importance of appropriate patient selection, coupled with rigorous evaluation of long-term outcomes, to refine its indications further
